Trial Profile
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 23 Feb 2010 Actual number of patients added to 60 as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Actual end date added to 1 Dec 2009 as reported by ClinicalTrials.gov.